
WonderTx
WonderTx is a YC Summer 2026 (S26) company. Based in San Francisco, CA, USA; Remote. Team of 3.
About WonderTx
Summary
WonderTx discovers oral small molecules that replace injectable drugs, targeting validated human biology where no pill exists today. Its platform solves a zero-shot inference problem: identifying chemical starting points for targets that have no prior training data, a task where standard interpolative AI fails. The company's extrapolative models reason beyond their training data and have produced experimentally confirmed binders across multiple structurally diverse targets, replacing the traditional early-discovery work of medicinal chemistry teams.
Business model
Undisclosed; platform validated on both internal and partner drug programs.
Go-to-market
WonderTx pursues its own internal drug programs and takes on partner programs, suggesting a hybrid biotech and platform-licensing approach targeting pharmaceutical collaborators.
From the Y Combinator listing
Extrapolative AI to unlock First-in-Class drugs
We’re an AI-native biotech, working on replacing needles with pills. Many drugs, like insulin or Ozempic, are wonderful except you have to inject them. We discover new molecules that you can take as a pill instead. Because the pills operate on biology which has been shown to be effective in people, rather than merely in animal models of disease, we avoid what has historically been the single biggest risk in drug discovery. This should dramatically increase our probability of success. There’s $200B of treatable diseases and validated human biology without a pill because discovery programs lack a tractable chemical starting point. This is a zero-shot inference problem, because these targets have no training data, so LLMs and other historical interpolative AI approaches are insufficient. Instead, we are building our own extrapolative frontier models that reason beyond their training data. Most critically, we have repeatedly validated our platform on both our own and partner programs. On 4 biologically- and structurally-diverse targets where we had zero training data, we successfully picked binders that were validated experimentally, with confirmation ranging from primary screen hits to crystallographic structures.
Facts
- Healthcare / Healthcare -> Therapeutics
- San Francisco, CA, USA; Remote
- 3
- Active
- Early
Founders (1)
Score every batch against your own thesis
GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.
How Accelerator intelligence works